Cargando…
Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm
Background: Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite ins...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Columbia Data Analytics, LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493167/ https://www.ncbi.nlm.nih.gov/pubmed/37701519 http://dx.doi.org/10.36469/001c.77484 |
_version_ | 1785104417326891008 |
---|---|
author | Goulden, Scott Shen, Qin Coleman, Robert L. Mathews, Cara Hunger, Matthias Pahwa, Ankit Schade, Rene |
author_facet | Goulden, Scott Shen, Qin Coleman, Robert L. Mathews, Cara Hunger, Matthias Pahwa, Ankit Schade, Rene |
author_sort | Goulden, Scott |
collection | PubMed |
description | Background: Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite instability–high advanced or recurrent EC. Objectives: The objective of this study was to compare overall survival (OS) and describe time to treatment discontinuation (TTD) for dostarlimab (GARNET Cohort A1 safety population) with an equivalent real-world external control arm receiving non-anti-programmed death (PD)-1/PD-ligand (L)1/2 treatments (constructed using data from a nationwide electronic health record–derived de-identified database and applied GARNET eligibility criteria). Methods: Propensity scores constructed from prognostic factors, identified by literature review and clinical experts, were used for inverse probability of treatment weighting (IPTW). Kaplan-Meier curves were constructed and OS/TTD was estimated (Cox regression model was used to estimate the OS-adjusted hazard ratio). Results: Dostarlimab was associated with a 52% lower risk of death vs real-world treatments (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.66). IPTW-adjusted median OS for dostarlimab (N=143) was not estimable (95% CI, 19.4–not estimable) versus 13.1 months (95% CI, 8.3-15.9) for real-world treatments (N = 185). Median TTD was 11.7 months (95% CI, 6.0-38.7) for dostarlimab and 5.3 months (95% CI, 4.1-6.0) for the real-world cohort. Discussion: Consistent with previous analyses, patients treated with dostarlimab had significantly longer OS than patients in the US real-world cohort after adjusting for the lack of randomization using stabilized IPTW. Additionally, patients had a long TTD when treated with dostarlimab, suggesting a favorable tolerability profile. Conclusion: Patients with advanced or recurrent EC receiving dostarlimab in GARNET had significantly lower risk of death than those receiving real-world non-anti-PD-(L)1/2 treatments. |
format | Online Article Text |
id | pubmed-10493167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Columbia Data Analytics, LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-104931672023-09-11 Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm Goulden, Scott Shen, Qin Coleman, Robert L. Mathews, Cara Hunger, Matthias Pahwa, Ankit Schade, Rene J Health Econ Outcomes Res Oncology Background: Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite instability–high advanced or recurrent EC. Objectives: The objective of this study was to compare overall survival (OS) and describe time to treatment discontinuation (TTD) for dostarlimab (GARNET Cohort A1 safety population) with an equivalent real-world external control arm receiving non-anti-programmed death (PD)-1/PD-ligand (L)1/2 treatments (constructed using data from a nationwide electronic health record–derived de-identified database and applied GARNET eligibility criteria). Methods: Propensity scores constructed from prognostic factors, identified by literature review and clinical experts, were used for inverse probability of treatment weighting (IPTW). Kaplan-Meier curves were constructed and OS/TTD was estimated (Cox regression model was used to estimate the OS-adjusted hazard ratio). Results: Dostarlimab was associated with a 52% lower risk of death vs real-world treatments (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.66). IPTW-adjusted median OS for dostarlimab (N=143) was not estimable (95% CI, 19.4–not estimable) versus 13.1 months (95% CI, 8.3-15.9) for real-world treatments (N = 185). Median TTD was 11.7 months (95% CI, 6.0-38.7) for dostarlimab and 5.3 months (95% CI, 4.1-6.0) for the real-world cohort. Discussion: Consistent with previous analyses, patients treated with dostarlimab had significantly longer OS than patients in the US real-world cohort after adjusting for the lack of randomization using stabilized IPTW. Additionally, patients had a long TTD when treated with dostarlimab, suggesting a favorable tolerability profile. Conclusion: Patients with advanced or recurrent EC receiving dostarlimab in GARNET had significantly lower risk of death than those receiving real-world non-anti-PD-(L)1/2 treatments. Columbia Data Analytics, LLC 2023-09-08 /pmc/articles/PMC10493167/ /pubmed/37701519 http://dx.doi.org/10.36469/001c.77484 Text en https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (4.0) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Oncology Goulden, Scott Shen, Qin Coleman, Robert L. Mathews, Cara Hunger, Matthias Pahwa, Ankit Schade, Rene Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm |
title | Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm |
title_full | Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm |
title_fullStr | Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm |
title_full_unstemmed | Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm |
title_short | Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm |
title_sort | outcomes for dostarlimab and real-world treatments in post-platinum patients with advanced/recurrent endometrial cancer: the garnet trial versus a us electronic health record-based external control arm |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493167/ https://www.ncbi.nlm.nih.gov/pubmed/37701519 http://dx.doi.org/10.36469/001c.77484 |
work_keys_str_mv | AT gouldenscott outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm AT shenqin outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm AT colemanrobertl outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm AT mathewscara outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm AT hungermatthias outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm AT pahwaankit outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm AT schaderene outcomesfordostarlimabandrealworldtreatmentsinpostplatinumpatientswithadvancedrecurrentendometrialcancerthegarnettrialversusauselectronichealthrecordbasedexternalcontrolarm |